{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:20:57Z","timestamp":1786684857793,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CPII19\/00008"],"award-info":[{"award-number":["CPII19\/00008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00681"],"award-info":[{"award-number":["PI23\/00681"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00922"],"award-info":[{"award-number":["PI21\/00922"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/01075"],"award-info":[{"award-number":["PI18\/01075"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP21\/00080"],"award-info":[{"award-number":["PMP21\/00080"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00189"],"award-info":[{"award-number":["PI20\/00189"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00526"],"award-info":[{"award-number":["PI22\/00526"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["EHD15PI05\/2016"],"award-info":[{"award-number":["EHD15PI05\/2016"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-140210OB-I00"],"award-info":[{"award-number":["PID2022-140210OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CEX2021-001136-S"],"award-info":[{"award-number":["CEX2021-001136-S"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-117116RB-I00"],"award-info":[{"award-number":["PID2020-117116RB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2022-136616OB-I00"],"award-info":[{"award-number":["PID2022-136616OB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008055","name":"Fundaci\u00f3n Eugenio Rodr\u00edguez Pascual","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Government of Castile and Le\u00f3n","doi-asserted-by":"publisher","award":["SA113P23"],"award-info":[{"award-number":["SA113P23"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.biopha.2024.117533","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T09:20:03Z","timestamp":1728811203000},"page":"117533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8723-6053","authenticated-orcid":false,"given":"Maitane","family":"Asensio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-1554","authenticated-orcid":false,"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Herraez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6730-2746","authenticated-orcid":false,"given":"Laura","family":"Perez-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Espinosa-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bueno-Sacristan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-5037","authenticated-orcid":false,"given":"Ana","family":"Peleteiro-Vigil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-0240","authenticated-orcid":false,"given":"Helen","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"P\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onat","family":"Kadioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Martinez-Chantar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias A.","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.G.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-1691","authenticated-orcid":false,"given":"Elisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.biopha.2024.117533_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2024.117533_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.biopha.2024.117533_bib3","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","article-title":"Current epidemiology of cholangiocarcinoma in Western countries","volume":"77","author":"Vithayathil","year":"2022","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117533_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117533_bib5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.dld.2023.08.052","article-title":"Intrahepatic cholangiocarcinoma: evolving strategies in management and treatment","volume":"56","author":"Bragazzi","year":"2024","journal-title":"Dig. Liver Dis."},{"issue":"1","key":"10.1016\/j.biopha.2024.117533_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL, EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2024.117533_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"issue":"3","key":"10.1016\/j.biopha.2024.117533_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clinre.2017.12.006","article-title":"Molecular bases of the poor response of liver cancer to chemotherapy","volume":"42","author":"Marin","year":"2018","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"5","key":"10.1016\/j.biopha.2024.117533_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103537","article-title":"ATP-binding cassette efflux transporters and MDR in cancer","volume":"28","author":"Pote","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"14","key":"10.1016\/j.biopha.2024.117533_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143524","article-title":"Expression of chemoresistance-associated ABC proteins in hepatobiliary, pancreatic and gastrointestinal cancers","volume":"14","author":"Marin","year":"2022","journal-title":"Cancers"},{"issue":"Suppl","key":"10.1016\/j.biopha.2024.117533_bib11","first-page":"125","article-title":"High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma","volume":"13","author":"Srimunta","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.biopha.2024.117533_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2362.2007.01916.x","article-title":"Expression of the multidrug resistance proteins MRP2 and MRP3 in human cholangiocellular carcinomas","volume":"38","author":"Rau","year":"2008","journal-title":"Eur. J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.biopha.2024.117533_bib13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s12253-018-0386-8","article-title":"Immunohistochemical assessment of the expression of biliary transportation proteins MRP2 and MRP3 in hepatocellular carcinoma and in cholangiocarcinoma","volume":"25","author":"Cirqueira","year":"2019","journal-title":"Pathol. Oncol. Res."},{"issue":"12","key":"10.1016\/j.biopha.2024.117533_bib14","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1073\/pnas.96.12.6914","article-title":"MRP3, an organic anion transporter able to transport anti-cancer drugs","volume":"96","author":"Kool","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2024.117533_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/1078-0432.CCR-09-1321","article-title":"P-glycoprotein (P-gp\/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide","volume":"16","author":"Lagas","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2024.117533_bib16","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1124\/dmd.111.038794","article-title":"Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate","volume":"39","author":"Vlaming","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"18","key":"10.1016\/j.biopha.2024.117533_bib17","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3748\/wjg.v11.i18.2748","article-title":"W. Tassaneeyakul, Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines","volume":"11","author":"Tepsiri","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2024.117533_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.31088","article-title":"MRP3-mediated chemoresistance in cholangiocarcinoma: target for chemosensitization through restoring SOX17 expression","volume":"72","author":"Lozano","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2024.117533_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2019.04.004","article-title":"ABCC3 is a novel target for the treatment of pancreatic cancer","volume":"73","author":"Adamska","year":"2019","journal-title":"Adv. Biol. Regul."},{"issue":"12","key":"10.1016\/j.biopha.2024.117533_bib20","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s11010-022-04475-4","article-title":"FAT1 downregulation enhances stemness and cisplatin resistance in esophageal squamous cell carcinoma","volume":"477","author":"Zhai","year":"2022","journal-title":"Mol. Cell Biochem."},{"issue":"5","key":"10.1016\/j.biopha.2024.117533_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155013","article-title":"Role of the drug transporter ABCC3 in breast cancer chemoresistance","volume":"11","author":"Balaji","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2024.117533_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115209","article-title":"Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells","volume":"165","author":"Sanchez-Martin","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2024.117533_bib23","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/pmic.200800842","article-title":"Proteome wide screening using peptide affinity capture","volume":"9","author":"Poetz","year":"2009","journal-title":"Proteomics"},{"issue":"4","key":"10.1016\/j.biopha.2024.117533_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/dmd.117.078626","article-title":"Direct quantification of cytochromes P450 and drug transporters-a rapid, targeted mass spectrometry-based immunoassay panel for tissues and cell culture lysates","volume":"46","author":"Weiss","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2024.117533_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116038","article-title":"Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with beta-caryophyllene oxide","volume":"170","author":"Ortiz-Rivero","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"W1","key":"10.1016\/j.biopha.2024.117533_bib26","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.117533_bib27","first-page":"1065","article-title":"Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib, Hepatology","volume":"58","author":"Herraez","year":"2013"},{"issue":"22","key":"10.1016\/j.biopha.2024.117533_bib28","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2024.117533_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"Dallakyan","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2024.117533_bib30","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1124\/dmd.108.022491","article-title":"Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3)","volume":"36","author":"Grant","year":"2008","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.biopha.2024.117533_bib31","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/hep.30656","article-title":"Causes of hOCT1-dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor-selective gene therapy","volume":"70","author":"Lozano","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.biopha.2024.117533_bib32","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0022-2275(20)32166-0","article-title":"Transport and biotransformation of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver","volume":"39","author":"Macias","year":"1998","journal-title":"J. Lipid Res"},{"issue":"5","key":"10.1016\/j.biopha.2024.117533_bib33","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1053\/gast.2001.28648","article-title":"Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia","volume":"121","author":"Rost","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2024.117533_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115681","article-title":"Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma","volume":"214","author":"Asensio","year":"2023","journal-title":"Biochem Pharm."},{"issue":"19","key":"10.1016\/j.biopha.2024.117533_bib35","first-page":"7225","article-title":"Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport","volume":"61","author":"Zeng","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2024.117533_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejps.2017.02.011","article-title":"Identification of novel MRP3 inhibitors based on computational models and validation using an in vitro membrane vesicle assay","volume":"103","author":"Ali","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.biopha.2024.117533_bib37","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022113415","article-title":"Placing steroid hormones within the human ABCC3 transporter reveals a compatible amphiphilic substrate-binding pocket","volume":"42","author":"Wang","year":"2023","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.biopha.2024.117533_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/bdd.2022","article-title":"TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux","volume":"37","author":"Cunha","year":"2016","journal-title":"Biopharm. Drug Dispos."},{"issue":"10","key":"10.1016\/j.biopha.2024.117533_bib39","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1158\/1535-7163.MCT-12-0966","article-title":"Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump","volume":"12","author":"Mazard","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.117533_bib40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.biocel.2014.03.026","article-title":"Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance","volume":"51","author":"Zhang","year":"2014","journal-title":"Int. J. Biochem Cell Biol."},{"key":"10.1016\/j.biopha.2024.117533_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.phrs.2017.01.024","article-title":"Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib","volume":"119","author":"Zhang","year":"2017","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.117533_bib42","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.18632\/oncotarget.6889","article-title":"MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma","volume":"7","author":"Tomonari","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.biopha.2024.117533_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/17425255.2015.981152","article-title":"New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition","volume":"11","author":"van der Schoor","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117533_bib44","first-page":"301","article-title":"Sorafenib plus irinotecan combination in patients with RAS-mutated metastatic colorectal cancer refractory to standard combined chemotherapies: a multicenter, randomized phase 2 trial (NEXIRI-2\/PRODIGE 27)","volume":"19","author":"Samalin","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.biopha.2024.117533_bib45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1-2","key":"10.1016\/j.biopha.2024.117533_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00508-010-1522-y","article-title":"Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report","volume":"123","author":"Pinter","year":"2011","journal-title":"Wien. Klin. Woche"},{"issue":"4","key":"10.1016\/j.biopha.2024.117533_bib47","first-page":"E30","article-title":"Cholangiocarcinoma: treatment with sorafenib extended life expectancy to greater than four years","volume":"4","author":"Chakunta","year":"2013","journal-title":"J. Gastrointest. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2024.117533_bib48","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s10637-011-9719-0","article-title":"SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma","volume":"30","author":"El-Khoueiry","year":"2012","journal-title":"Invest N. Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.117533_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/sj.bjc.6605458","article-title":"Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial","volume":"102","author":"Bengala","year":"2010","journal-title":"Br. J. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224014197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224014197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:23:18Z","timestamp":1778541798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224014197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":49,"alternative-id":["S0753332224014197"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117533","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.117533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117533"}}